CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results

2008-07-15 07:30:00

    ATLANTA, July 15 /EMWPresswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY),

a biomaterials, medical device and tissue processing company, announced

today that second quarter 2008 financial results will be released on

Thursday, July 31, 2008. The Company will hold a teleconference call and

live webcast at 10:00 a.m. Eastern Time, July 31, 2008, to discuss the

results, followed by a question and answer session hosted by Steven G.

Anderson, president and CEO of CryoLife, Inc.



    To listen to the live teleconference, please dial 201-689-8261 a few

minutes prior to 10:00 a.m. A replay of the teleconference will be

available July 31 through August 7 and can be accessed by calling (toll

free) 877-660-6853 or 201-612-7415. The account number for the replay is

244 and the conference number is 290785.



    The live webcast and replay can be accessed by going to the Investor

Relations section of the CryoLife web site at http://www.cryolife.com and

selecting the heading Webcasts & Presentations.



    About CryoLife, Inc.



    Founded in 1984, CryoLife, Inc. is a leader in the processing and

distribution of implantable living human tissues for use in cardiac and

vascular surgeries throughout the United States and Canada. The Company

recently received FDA clearance for the CryoValve(R) SG pulmonary human

heart valve, processed using CryoLife's proprietary SynerGraft(R)

Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as

an adjunct to sutures and staples for use in adult patients in open

surgical repair of large vessels. BioGlue is also CE marked in the European

Community and approved in Canada and Australia for use in soft tissue

repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much

of the U.S. for use in cardiac and vascular surgery and in the United

Kingdom and Germany for cardiac, vascular, and general surgery, subject to

certain exclusions. The Company also distributes the CryoLife-O'Brien(R)

stentless porcine heart valve, which is CE marked for distribution within

the European Community.



    For additional information about the company, visit CryoLife's Web

site:




http://www.cryolife.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions